Literature DB >> 3119265

Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS.

B E Kloster1, P A John, L E Miller, L A Rubin, D L Nelson, D C Blair, R H Tomar.   

Abstract

Utilizing an enzyme-linked immunosorbent assay, we detected elevated serum levels of soluble interleukin 2 receptors (SIL-2R) in 73% of patients with acquired immunodeficiency syndrome (AIDS), 80% of AIDS-related complex patients, 78% of anti-HIV-positive lymphadenopathy syndrome patients, 85% of HIV-antibody-positive hemophiliacs, and 80% of anti-HIV-positive asymptomatic homosexual males, iv drug abusers, and heterosexual contacts. Of the subjects with no demonstrable antibody to HIV, 29% of hemophiliacs, 12% of adult homosexual males and iv drug abusers, and none of the patients with lymphadenopathy had elevated SIL-2R. Overall, only 5 of 40 antibody-negative "high-risk" individuals had SIL-2R values greater than the reference interval whereas 108 of 138 antibody-positive individuals had elevated values (chi 2 = 57.85, P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119265     DOI: 10.1016/0090-1229(87)90095-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  16 in total

1.  Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.

Authors:  L A Santana-Blank; M Castes; M E Rojas; F Vargas; D Scott-Algara
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

2.  Longitudinal survey in an endemic region of plasma soluble interleukin-2 receptor and antibody levels in Plasmodium falciparum malaria.

Authors:  B F Chumpitazi; F Peyron; J Simon; C Boudin; I Sheick-Zakiuddin; S Picot; P Ambroise-Thomas
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

3.  Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.

Authors:  G H Bock; J R Ongkingco; L T Patterson; J Ruley; L R Schroepfer; D L Nelson
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

4.  Soluble CD8 and CD25 in serum of patients after heart transplantation.

Authors:  P L Wijngaard; A Van der Meulen; F H Gmelig Meyling; N De Jonge; H J Schuurman
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

5.  Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour.

Authors:  S Sharma; K Saha; R N Shinghal; G B Malik
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Soluble Il-2 receptor serum levels--a marker for disease progression in patients with HIV-1 infection.

Authors:  C Schulte; M Meurer
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

7.  Immune activation during infancy in healthy humans.

Authors:  A G Cummins; B A Eglinton; A Gonzalez; D M Roberton
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

8.  Expression of interleukin 2 receptors by monocytes from patients with acquired immunodeficiency syndrome and induction of monocyte interleukin 2 receptors by human immunodeficiency virus in vitro.

Authors:  J B Allen; N McCartney-Francis; P D Smith; G Simon; S Gartner; L M Wahl; M Popovic; S M Wahl
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

9.  Soluble IL-2 receptor and tumour necrosis factor-alpha in plasma of haemophilia patients infected with HIV.

Authors:  I L Noronha; V Daniel; K Schimpf; G Opelz
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

10.  Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with non-resectable lung cancer.

Authors:  J Vibe-Petersen; N Tvede; M Diamant; A A Kjerulff; H R Sørensen; V Andersen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.